Guilin Sanjin: Lamotrigine tablets are expected to be selected for the twelfth batch of national drug collection.

Guilin Sanjin Announcement: The company's wholly-owned subsidiary, Hunan Sanjin, participated in the twelfth batch of national centralized procurement of medicines. The product, Lamotrigine tablets, is expected to be selected in this centralized procurement. The procurement period will run from the date of the selection results until December 31, 2029. The sales revenue of this product in 2025 is estimated to be 73.8999 million yuan, accounting for 3.61% of the company's operating income for the fiscal year 2025.